This exactly why i wrote a follow up email to them. There has been no tangible progress despite years of the same cut and paste response from HQ.
This has resulted in repeated capital raises that dilute shareholder value, while millions of dollars have been invested without a return.
There needs to be a tangible and measurable way for out-licensing progress to be reported to shareholders, as IMU management has been assuring us of progress in this area for years without achieving meaningful results. I specifically asked that If this has not been achieved to date, what is being done differently to ensure success since the phase 2 completion for Hervaxx and the deprioritisation of B-Cell platform?
Progressing the science is one thing - being able to sell it is another. Highly paid staff with this very remit have come and gone (after being on the phone day and night with BP apparently) and with thousands of dollars in bonuses without success.
IMU Price at posting:
3.7¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)